tirzepatide news 2025 New clinical trial: Zepbound (tirzepatide) helped adults lose an average of 20.2% of their body weight—around 50 lbs—over 72 weeks, outperforming Wegovy's 13.7% (~33 lbs). Credit to: https://www.healthline.com/health-news/zepbound-wegovy-weight-loss Great news! 🎉 Zepbound is

The peptide's predictable dose-response and extended stability in culture media have made it a preferred growth factor supplement in CHO cell culture, stem cell expansion, and primary cell isolation protocols across hundreds of published studies

(2015) "MOTS-c promotes metabolic homeostasis." Published in Cell Metabolism

Mounjaro has shown greater weight loss outcomes compared to Retatrutide in clinical trials, but both medications offer effective weight management options, with individual considerations influencing the choice between them

Meningkatkan sensitivitas insulin Resistensi insulin dapat menyebabkan perkembangan pada diabetes tipe 2